

## LEVANTE DIABETES

### How to Manage Cardiorenal Risk in Type 2 Diabetes Today

11-12 December 2026 - MOVENPICK HOTEL, Bari

**PROVIDER:** Centro Italiano Congressi CIC Sud

**ID PROVIDER:** 1833

**ID EVENTO:** 496587

**EDIZIONE:** 1

**OBIETTIVO FORMATIVO:** Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura

**N. CREDITI:** 9

## RATIONALE

Type 2 diabetes mellitus represents one of the greatest global health challenges in terms of prevalence, clinical impact and economic burden. Its management has undergone a significant evolution in recent years thanks to the introduction of new drug classes, particularly sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors), which have demonstrated beneficial effects not only on glycaemic control, but also on the prevention and management of cardiovascular and renal complications.

This new therapeutic vision enables a paradigm shift: from the traditional “treat to target” approach focused solely on achieving glycaemic goals, towards a “treat to benefit” and “treat to prevent” model centred on organ protection and improvement of the patient’s overall clinical outcomes.

The most recent scientific evidence, derived from both randomised controlled trials (RCTs) and real-world (RW) studies, confirms the efficacy of SGLT2 inhibitors in reducing the risk of chronic kidney disease progression and improving outcomes in patients with heart failure, even in the absence of diabetes. Of particular relevance is the synergistic role of combination therapy with GLP-1 receptor agonists, which further strengthens the strategy of early and comprehensive prevention.

This educational event aims to provide participants with a comprehensive, in-depth and clinically oriented update on the current and future role of SGLT2 inhibitors in the management of type 2 diabetes. Through keynote lectures and interactive discussions, key topics will be addressed, including early diagnosis, cardio-renal risk stratification, personalised therapeutic choice and the practical implications of using SGLT2 inhibitors in everyday clinical practice.

The participation of Italian and international experts will offer a multidisciplinary and up-to-date perspective on the potential and challenges of SGLT2 inhibitor use, contributing to increasingly effective, sustainable and patient-centred management of type 2 diabetes.

## FRIDAY, DECEMBER 11

Welcome lunch

- 12.15 Registration
- 13.00 Introduction  
Francesco Giorgino

### SESSION 1

Chair: Francesco Giorgino

- 13.15 **How to define and stratify cardiovascular risk in people with type 2 diabetes**  
Nikolaus Marx
- 13.35 **Update on recent recommendations for the management of type 2 diabetes**  
Francesco Giorgino
- 13.55 **Early intervention in the management of type 2 diabetes**  
Stefano Del Prato
- 14.15 Discussion of the topics presented
- 14.45 **RCTs and RWE with SGLT-2 inhibitors to reduce CKD and CVD/HF risks**  
Luigi Laviola
- 15.05 **Talk show and sharing clinical experience: Early combination vs. stepwise therapy**  
Andrea Giaccari, Domenico Tricò
- 15.40 Discussion of the topics presented

16.15 Coffee Break

### SESSION 2

Chair: Salvatore De Cosmo

- 16.40 **Prevention and therapy of CKD in diabetes: SGLT-2 inhibitors, finerenone, other?**  
David Wheeler
- 17.00 **Talk show and sharing clinical experience: The patient at low vs high renal risk**  
Mario Luca Morieri, Anna Solini
- 17.35 Discussion of the topics presented
- 18.30 End of Session

**SATURDAY, DECEMBER 12**

**SESSION 3**

Chair: Francesco Giorgino

- 09.10 **SGLT-2 inhibitors beyond HF and CKD**  
Gianluca Perseghin
- 09.30 **Prevention of heart failure in clinical practice**  
Raffaele Napoli
- 09.50 **Treatment of heart failure in clinical practice**  
David Sjöström
- 10.10 Discussion of the topics presented
- 10.50 Coffee Break
- 11.10 **Talk show and sharing clinical experience:**  
**Type 2 diabetes with HFpEF**  
Irene Caruso, Ernesto Maddaloni
- 12.10 **Behind the horizon**  
**Realizing the potential of AI in diabetes care**  
**(NO CME)**  
Peter Fenici
- 12.30 Final Discussion of the topics presented
- 13.30 Conclusions
- End of the Meeting

**Acronimo**

**Significato**

|               |                                                       |
|---------------|-------------------------------------------------------|
| <b>RCTs</b>   | <b>Randomized Controlled Trials</b>                   |
| <b>RWE</b>    | <b>Real-World Evidence</b>                            |
| <b>SGLT-2</b> | <b>Sodium-Glucose Cotransporter-2</b>                 |
| <b>CKD</b>    | <b>Chronic Kidney Disease</b>                         |
| <b>CVD</b>    | <b>Cardiovascular Disease</b>                         |
| <b>HF</b>     | <b>Heart Failure</b>                                  |
| <b>HFpEF</b>  | <b>Heart Failure with preserved Ejection Fraction</b> |
| <b>AI</b>     | <b>Artificial Intelligence</b>                        |

## RELATORI

| COGNOME E NOME     | LAUREA               | SPECIALIZZAZIONE                                                | AFFILIAZIONE                                                                                                                                                                                                   |
|--------------------|----------------------|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CARUSO IRENE       | MEDICINA E CHIRURGIA | ENDOCRINOLOGIA                                                  | DIRIGENTE MEDICO, U.O.C. ENDOCRINOLOGIA – AZIENDA OSPEDALIERO-UNIVERSITARIA CONSORZIALE POLICLINICO DI <b>BARI</b>                                                                                             |
| DEL PRATO STEFANO  | MEDICINA E CHIRURGIA | ENDOCRINOLOGIA – MEDICINA INTERNA                               | PROFESSORE EMERITO DI ENDOCRINOLOGIA – DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE, UNIVERSITÀ DI <b>PISA</b>                                                                                              |
| GIACCARI ANDREA    | MEDICINA E CHIRURGIA | ENDOCRINOLOGIA                                                  | PROFESSORE ASSOCIATO DI ENDOCRINOLOGIA – UNIVERSITÀ CATTOLICA DEL SACRO CUORE; RESPONSABILE CENTRO MALATTIE ENDOCRINE E METABOLICHE – FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS, <b>ROMA</b> |
| GIORGINO FRANCESCO | MEDICINA E CHIRURGIA | ENDOCRINOLOGIA                                                  | PROFESSORE ORDINARIO DI ENDOCRINOLOGIA – UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO; DIRETTORE U.O.C. ENDOCRINOLOGIA – AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI <b>BARI</b>                              |
| LAVIOLA LUIGI      | MEDICINA E CHIRURGIA | ENDOCRINOLOGIA E MALATTIE DEL RICAMBIO                          | PROFESSORE ORDINARIO DI ENDOCRINOLOGIA – UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO; DIMEPRE-J / POLICLINICO DI <b>BARI</b>                                                                                      |
| MADDALONI ERNESTO  | MEDICINA E CHIRURGIA | ENDOCRINOLOGIA E MALATTIE DEL METABOLISMO                       | PROFESSORE ASSOCIATO DI ENDOCRINOLOGIA – DIPARTIMENTO DI MEDICINA SPERIMENTALE, SAPIENZA UNIVERSITÀ DI <b>ROMA</b>                                                                                             |
| MARX NIKOLAUS      | MEDICINA             | MEDICINA INTERNA – CARDIOLOGIA – TERAPIA INTENSIVA INTERNISTICA | DIRETTORE, CLINICA DI CARDIOLOGIA, ANGIOLOGIA E TERAPIA INTENSIVA INTERNISTICA – UNIVERSITY HOSPITAL RWTH <b>AACHEN, GERMANIA</b>                                                                              |
| MORIERI MARIO LUCA | MEDICINA E CHIRURGIA | MEDICINA INTERNA / MALATTIE DEL METABOLISMO                     | RICERCATORE – DIPARTIMENTO DI MEDICINA (DIMED), UNIVERSITÀ DEGLI STUDI DI <b>PADOVA</b>                                                                                                                        |
| NAPOLI RAFFAELE    | MEDICINA E CHIRURGIA | MEDICINA INTERNA                                                | PROFESSORE ORDINARIO – DIPARTIMENTO DI SCIENZE MEDICHE TRASLAZIONALI, UNIVERSITÀ DEGLI STUDI DI <b>NAPOLI FEDERICO II</b> ; RESPONSABILE PROGRAMMA DI I FASCIA DI MEDICINA INTERNA DI PRECISIONE               |

|                       |                      |                                                                                                    |                                                                                                                                                                                                                                               |
|-----------------------|----------------------|----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PERSEGHIN<br>GIANLUCA | MEDICINA E CHIRURGIA | ENDOCRINOLOGIA E<br>MALATTIE DEL<br>RICAMBIO                                                       | PROFESSORE ORDINARIO DI<br>ENDOCRINOLOGIA – DIPARTIMENTO<br>DI MEDICINA E CHIRURGIA,<br>UNIVERSITÀ DEGLI STUDI DI<br><b>MILANO-BICOCCA</b> ; DIRETTORE<br>DELLA SCUOLA DI SPECIALIZZAZIONE<br>IN ENDOCRINOLOGIA E MALATTIE<br>DEL METABOLISMO |
| SJÖSTRÖM DAVID        | MEDICINA             |                                                                                                    | LATE-STAGE DEVELOPMENT,<br>CARDIOVASCULAR, RENAL AND<br>METABOLISM,<br>BIOPHARMACEUTICALS R&D –<br>ASTRAZENECA, <b>GOTHENBURG,</b><br><b>SWEDEN</b>                                                                                           |
| SOLINI ANNA           | MEDICINA E CHIRURGIA | DIABETOLOGIA E<br>MALATTIE DEL<br>METABOLISMO –<br>GASTROENTEROLOGIA<br>ED ENDOSCOPIA<br>DIGESTIVA | PROFESSORE ASSOCIATO –<br>DIPARTIMENTO DI PATOLOGIA<br>CHIRURGICA, MEDICA,<br>MOLECOLARE E DELL'AREA CRITICA,<br>UNIVERSITÀ DI <b>PISA</b>                                                                                                    |
| TRICÒ DOMENICO        | MEDICINA E CHIRURGIA | MEDICINA INTERNA                                                                                   | PROFESSORE ASSOCIATO –<br>DIPARTIMENTO DI MEDICINA<br>CLINICA E SPERIMENTALE,<br>UNIVERSITÀ DI <b>PISA</b>                                                                                                                                    |
| WHEELER DAVID         | MEDICINA             | NEFROLOGIA                                                                                         | PROFESSOR OF KIDNEY MEDICINE –<br>DEPARTMENT OF RENAL MEDICINE /<br>CENTRE FOR KIDNEY AND BLADDER<br>HEALTH, UNIVERSITY COLLEGE<br>LONDON (UCL), <b>LONDRA</b>                                                                                |